[go: up one dir, main page]

MX2024015058A - Terapia combinada de agente activo anti proteína de muerte programada 1 (pd-1), agente activo anti dominio 3 de inmunoglobulina y mucina de linfocitos t (tim-3) y agente activo anti gen 3 de activación de linfocitos (lag-3) para tratar el cáncer - Google Patents

Terapia combinada de agente activo anti proteína de muerte programada 1 (pd-1), agente activo anti dominio 3 de inmunoglobulina y mucina de linfocitos t (tim-3) y agente activo anti gen 3 de activación de linfocitos (lag-3) para tratar el cáncer

Info

Publication number
MX2024015058A
MX2024015058A MX2024015058A MX2024015058A MX2024015058A MX 2024015058 A MX2024015058 A MX 2024015058A MX 2024015058 A MX2024015058 A MX 2024015058A MX 2024015058 A MX2024015058 A MX 2024015058A MX 2024015058 A MX2024015058 A MX 2024015058A
Authority
MX
Mexico
Prior art keywords
active agent
lag
tim
combination therapy
treating cancer
Prior art date
Application number
MX2024015058A
Other languages
English (en)
Inventor
Paul E Hoyle
Zhiwan Dong
Thomas Condamine
Nithya Srinivasan
John E Janik
Kevin N Heller
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MX2024015058A publication Critical patent/MX2024015058A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente descripción proporciona una terapia combinada que comprende: (i) un agente activo que se une a PD1 (por ejemplo, un anticuerpo anti-PD-1), (ii) un agente activo que se une a TIM-3 (por ejemplo, un anticuerpo anti-TIM-3), y/o (iii) un agente activo que se une a LAG-3 (por ejemplo, un anticuerpo anti-LAG-3). La presente descripción proporciona composiciones farmacéuticas de estos, usos de estos, y métodos de tratamiento que incluyen administrar la terapia combinada a un sujeto, incluidos métodos para tratar cáncer.
MX2024015058A 2022-06-07 2024-12-05 Terapia combinada de agente activo anti proteína de muerte programada 1 (pd-1), agente activo anti dominio 3 de inmunoglobulina y mucina de linfocitos t (tim-3) y agente activo anti gen 3 de activación de linfocitos (lag-3) para tratar el cáncer MX2024015058A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263349876P 2022-06-07 2022-06-07
US202263405243P 2022-09-09 2022-09-09
PCT/US2023/067996 WO2023240082A2 (en) 2022-06-07 2023-06-06 Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer

Publications (1)

Publication Number Publication Date
MX2024015058A true MX2024015058A (es) 2025-04-02

Family

ID=89119039

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024015058A MX2024015058A (es) 2022-06-07 2024-12-05 Terapia combinada de agente activo anti proteína de muerte programada 1 (pd-1), agente activo anti dominio 3 de inmunoglobulina y mucina de linfocitos t (tim-3) y agente activo anti gen 3 de activación de linfocitos (lag-3) para tratar el cáncer

Country Status (12)

Country Link
US (1) US20230416367A1 (es)
EP (1) EP4536277A2 (es)
JP (1) JP2025519495A (es)
KR (1) KR20250035054A (es)
CN (1) CN119630421A (es)
AU (1) AU2023285080A1 (es)
CA (1) CA3258446A1 (es)
CL (1) CL2024003729A1 (es)
IL (1) IL317382A (es)
MX (1) MX2024015058A (es)
TW (1) TW202417479A (es)
WO (1) WO2023240082A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX389710B (es) * 2016-05-27 2025-03-20 Agenus Inc Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
TW202440634A (zh) * 2023-03-08 2024-10-16 美商英塞特公司 用於治療癌症之抗－ｐｄ－１活性劑、抗－ｔｉｍ－３活性劑及抗－ｌａｇ－３活性劑之組合療法
WO2025229157A1 (en) * 2024-05-01 2025-11-06 Immutep S.A.S. Combination therapy using lag-3 protein and anti-pd-1 inhibitor with radiotherapy for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEAP202215554A (en) * 2015-07-30 2022-06-10 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
MX389710B (es) * 2016-05-27 2025-03-20 Agenus Inc Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
KR20230133934A (ko) * 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
US11939380B2 (en) * 2017-04-05 2024-03-26 Les Laboratoires Servier Combination therapies targeting PD-1, TIM-3, and LAG-3
AU2018292618A1 (en) * 2017-06-27 2019-12-19 Novartis Ag Dosage regimens for anti-TIM-3 antibodies and uses thereof

Also Published As

Publication number Publication date
EP4536277A2 (en) 2025-04-16
KR20250035054A (ko) 2025-03-11
IL317382A (en) 2025-02-01
TW202417479A (zh) 2024-05-01
WO2023240082A3 (en) 2024-02-01
JP2025519495A (ja) 2025-06-26
AU2023285080A1 (en) 2025-01-02
CN119630421A (zh) 2025-03-14
CL2024003729A1 (es) 2025-08-01
US20230416367A1 (en) 2023-12-28
WO2023240082A2 (en) 2023-12-14
CA3258446A1 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
MX2024015058A (es) Terapia combinada de agente activo anti proteína de muerte programada 1 (pd-1), agente activo anti dominio 3 de inmunoglobulina y mucina de linfocitos t (tim-3) y agente activo anti gen 3 de activación de linfocitos (lag-3) para tratar el cáncer
CR20230404A (es) Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d
EA202190630A1 (ru) Способы комбинированной терапии
MX2024013016A (es) Anticuerpos anti-pd1 para usarse en el tratamiento del cancer
PH12021552675A1 (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
MX2023006318A (es) Compuesto de heteroarilcarboxamida.
CA2939464A1 (en) Use of anti-ccr5 antibodies in graft versus host disease
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
MX2023004399A (es) Tratamiento de combinacion.
MX2022007790A (es) Terapia para el tratamiento del cancer.
MX2023013890A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos.
MX2020002429A (es) Compuestos para reducir la viscosidad de las formulaciones biologicas.
WO2019199667A3 (en) Pladienolide compounds and their use
EA202092136A1 (ru) Способы лечения рака с помощью комбинации антитела к pd-1 и конъюгата антитела к тканевому фактору и лекарственного средства
WO2022060986A3 (en) Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy
MX2022008216A (es) Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo.
WO2021056025A3 (en) Anti-epha10 antibodies and methods of use thereof
MX2025004037A (es) Inhibidor de perk hc-5404 en combinacion con un anticuerpo anti-pd-1 y/o un agente antiangiogentico para su uso en el tratamiento del cancer
WO2025019819A3 (en) Small molecule protein degraders of kras g12d mutant
MX2021009189A (es) Belantamab mafodotin en combinación con pembrolizumab para el tratamiento del cáncer.
MX2022007516A (es) Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos.
WO2024187137A3 (en) Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer
MX2025000682A (es) Composicion farmaceutica de anticuerpo anti-cd20 y uso de la misma
CR20230473A (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1.
MX2024005406A (es) Reduccion de corticosteroides en el tratamiento con anticuerpos anti-cd38.